Welcome to our dedicated page for Altimmune SEC filings (Ticker: ALT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Altimmune, Inc. filings document a late clinical-stage biopharmaceutical issuer focused on pemvidutide for serious liver diseases, along with the capital structure used to support that development. Its Form 8-K reports cover operating-result announcements, underwriting agreements, registered direct and at-the-market equity programs, pre-funded warrants, common stock warrants and loan agreement amendments.
Altimmune’s proxy and annual meeting materials disclose shareholder voting matters, governance procedures, executive compensation information and amendments to its certificate of incorporation, including authorized-share matters. The filings also identify its common stock as listed on The Nasdaq Global Market under the symbol ALT.
Altimmune, Inc. director Klaus Schafer received a grant of stock options as part of non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The options relate to 48,800 shares of common stock and were granted at no cost. They vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on his continued board service. After this grant, he holds 48,800 options directly.
Altimmune, Inc. director Wayne Pisano received a grant of stock options to acquire 48,800 shares of common stock at an exercise price of $2.82 per share. The options were issued as part of the company’s non-employee director compensation policy.
The options expire on May 1, 2036 and cover 48,800 underlying shares of common stock. The shares underlying the option vest and become exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on Mr. Pisano’s continued service.
Altimmune, Inc. director Philip Hodges received a grant of stock options as part of his non-employee director compensation. The award covers 48,800 options to buy common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The 48,800 underlying shares become vested and exercisable in substantially equal monthly installments over the 12 months following May 1, 2026, as long as Hodges continues to serve the company through each vesting date. This is a compensation-related award rather than an open-market purchase or sale.
Altimmune, Inc. reporting persons RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah disclose beneficial ownership of 13,000,000 shares of common stock (shared voting and dispositive power). The filing states this equals 6.5% of the class, calculated using 130,105,177 shares outstanding as of March 13, 2026 and 64,250,000 shares issued in the public offering that closed on April 24, 2026. The Fund directly holds 6,500,000 shares and Common Warrants exercisable for up to 6,500,000 shares; RA Capital and the named individuals describe delegated voting/dispositive arrangements and disclaim certain beneficial‑ownership statuses for specific regulatory purposes.
Altimmune, Inc. director John Gill received a grant of stock options as part of his non-employee director compensation. He was awarded options for 48,800 shares of common stock at an exercise price of $2.82 per share, expiring on May 1, 2036.
The options were granted at no cost and will vest in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on his continued service. This is a routine, compensation-related award rather than an open-market purchase or sale.
Altimmune director Mitchel Sayare reported receiving a grant of 48,800 stock options to buy Altimmune common stock. The options have an exercise price of $2.82 per share and expire on May 1, 2036. They were awarded under the company’s non-employee director compensation policy and vest in substantially equal monthly installments over the 12 months following May 1, 2026, contingent on continued board service.
Altimmune, Inc. Schedule 13G: Deep Track filing reports beneficial ownership disclosures for its affiliates and David Kroin. The filing states 19,417,221 shares (9.99%) reported for the named reporting person with shared voting and dispositive power as of April 30, 2026.
The disclosure uses a base of 194,366,579 shares (calculated from 194,199,358 shares outstanding as of April 24, 2026 plus 167,221 convertible shares). The filing also describes Pre-Funded Warrants (10,750,000) and Warrants (30,000,000) subject to a 9.99% Maximum Percentage exercise limitation that prevents exercises causing ownership to exceed 9.99%.
Altimmune, Inc. completed an underwritten public offering of 64,250,000 shares of common stock at $3.00 per share, each sold with an accompanying common stock warrant. The company also issued, in lieu of shares to certain investors, pre-funded warrants to purchase up to 10,750,000 shares at $2.999 per pre-funded warrant.
Altimmune expects net proceeds of approximately $211.2 million, to be used with existing cash to advance clinical development of pemvidutide, including preparation for a global pivotal Phase 3 trial in metabolic dysfunction-associated steatohepatitis (MASH), to begin pre-commercial activities for its lead program, and for general corporate purposes.
Each common stock warrant is exercisable at $3.00 per share and remains exercisable until the earlier of five years from issuance or 45 days after a successful Phase 3 pemvidutide MASH data readout, subject to Beneficial Ownership Limitations generally at 4.99% or 9.99%, up to 19.99%. Pre-funded warrants have a $0.001 exercise price, do not expire, and also carry a 9.99% ownership cap, adjustable up to 19.99%.
Altimmune, Inc. is conducting an underwritten offering of 64,250,000 shares of common stock together with accompanying common stock warrants and, in lieu of certain shares to some investors, pre-funded warrants to purchase up to 10,750,000 shares. The offering includes common stock warrants exercisable for up to 75,000,000 shares with a $3.00 exercise price.
Proceeds (net ~$211.2M) are intended to fund a planned global Phase 3 trial of pemvidutide in MASH and for working capital and general corporate purposes. The common stock warrants expire on the earlier of five years after issuance or 45 days after a public announcement of a successful Phase 3 pemvidutide readout. The pre-funded warrants have a $0.001 exercise price and do not expire.
Altimmune, Inc. filed a preliminary prospectus supplement to offer shares of common stock, pre-funded warrants and common stock warrants pursuant to its shelf registration statements. The company intends to use net proceeds to fund a planned global Phase 3 trial of pemvidutide in MASH and for working capital and general corporate purposes. The supplement notes pemvidutide Phase 2b topline efficacy (MASH resolution: 58.2% and 52.1% for two doses versus 19.9% for placebo) and that the FDA granted Breakthrough Therapy Designation in MASH. The filing discloses 110,882,735 shares outstanding as of December 31, 2025 and that the company filed to increase authorized common shares to 400,000,000 on April 16, 2026. The prospectus estimates available cash is expected to fund operations through a topline Phase 3 readout anticipated in the first half of 2029, subject to assumptions.
Altimmune, Inc. filed a preliminary prospectus supplement to offer shares of common stock, pre-funded warrants and common stock warrants pursuant to its shelf registration statements. The company intends to use net proceeds to fund a planned global Phase 3 trial of pemvidutide in MASH and for working capital and general corporate purposes. The supplement notes pemvidutide Phase 2b topline efficacy (MASH resolution: 58.2% and 52.1% for two doses versus 19.9% for placebo) and that the FDA granted Breakthrough Therapy Designation in MASH. The filing discloses 110,882,735 shares outstanding as of December 31, 2025 and that the company filed to increase authorized common shares to 400,000,000 on April 16, 2026. The prospectus estimates available cash is expected to fund operations through a topline Phase 3 readout anticipated in the first half of 2029, subject to assumptions.